Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
- Author:
Xu GAO
1
;
Tie ZHOU
;
Yuan-Jie TANG
;
Xin LU
;
Ying-Hao SUN
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antineoplastic Agents, Hormonal; therapeutic use; Combined Modality Therapy; Dose-Response Relationship, Drug; Flutamide; therapeutic use; Goserelin; therapeutic use; Humans; Male; Middle Aged; Neoadjuvant Therapy; methods; Prostate-Specific Antigen; blood; Prostatectomy; methods; Prostatic Neoplasms; blood; drug therapy; surgery; Retrospective Studies; Treatment Outcome
- From: Asian Journal of Andrology 2009;11(1):127-130
- CountryChina
- Language:English
- Abstract: The purpose of this study is to evaluate the therapeutic effect of radical prostatectomy combined with preoperative neoadjuvant hormonal ablation therapy for prostate cancer (PCa). In this study, a total of 31 patients with local PCa underwent radical prostatectomy; of these, 12 patients underwent preoperative hormonal deprivation with a combination of goserelin and flutamide for a period of 5.6 months. Data regarding clinical characteristics were compared between the neoadjuvant therapy and radical prostatectomy groups. A total of 31 patients received pelvic lymph node clearance, and the rate of positive lymph nodes was 12.9% (4/31). Serum prostate-specific antigen (PSA) was 8.9 +/- 1.2 microg L(-1) after the neoadjuvant therapy and 0.4 +/- 0.3 microg L(-1) one month after the radical prostatectomy. There were significant differences in the positive surgical margins, seminal vesicle invasion and lymph node metastasis between the neoadjuvant therapy group (n = 12) and the radical prostatectomy group (n = 19, P < 0.01). The resulsts indicates that preoperative hormonal deprivation induced by goserelin and flutamide can decrease clinical and pathological staging, but assessment of its influence on long-term prognosis requires further study.
